ArticleHuman vaccines & immunotherapeutics2025
Closing the hepatitis B birth-dose gap in Cameroon: Global evidence and policy imperatives.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus infects an estimated 254 million people worldwide and caused 1.1 million deaths in 2022. In the WHO African Region, about 65 million people live with chronic HBV (HBsAg prevalence 5.8%). In Cameroon, pooled HBsAg prevalence was 11.2% among pre-2005 cohorts, born before infant HBV vaccination, versus 0.7% in a hospital-based cohort of children recruited in 2009-2010 among post-2005 births (not nationally representative). Nonetheless, HepB birth-dose coverage was 0% in 2024; infection at birth leads to chronic HBV in 80-90% of cases, with roughly one in four dying prematurely. Completion of the infant series is 68%, with subnational gaps leaving many children unprotected. Cameroon's selective policy restricts the timely birth-dose to infants of known HBsAg-positive mothers, further perpetuating inequities. In hard-to-reach areas, antenatal screening is limited and home deliveries are common; the same children who miss the infant series also miss the birth-dose. Leveraging high-coverage BCG platforms could help close this gap and protect newborns within 24 hours of birth. This commentary reviews global evidence for the birth-dose, analyzes Cameroon's policy gaps, and proposes equity-focused actions for universal birth-dose adoption, strengthened delivery systems and supply chains, and data-driven governance to reach WHO's 2030 elimination targets in Cameroon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.